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Protein kinase GWe have previously reported that estradiol can protect heart mitochondria from the ischemia-induced
mitochondrial permeability transition pore-related release of cytochrome c and subsequent apoptosis. In this
study we investigated whether the effect of 17-beta-estradiol on ischemia-induced mitochondrial
dysfunctions and apoptosis is mediated by activation of signaling protein kinases in a Langendorff-perfused
rat heart model of stop-ﬂow ischemia. We found that pre-perfusion of non-ischemic hearts with 100 nM
estradiol increased the resistance of subsequently isolated mitochondria to the calcium-induced opening of
mitochondrial permeability transition pore and this was mediated by protein kinase G. Loading of the hearts
with estradiol prevented ischemia-induced loss of cytochrome c from mitochondria and respiratory
inhibition and these effects were reversed in the presence of the inhibitor of Akt kinase, NO synthase
inhibitor L-NAME, guanylyl cyclase inhibitor ODQ and protein kinase G inhibitor KT5823. Estradiol prevented
ischemia-induced activation of caspases and this was also reversed by KT5823. These ﬁndings suggest that
estradiol may protect the heart against ischemia-induced injury activating the signaling cascade which
involves Akt kinase, NO synthase, guanylyl cyclase and protein kinase G, and results in blockage of
mitochondrial permeability transition pore-induced release of cytochrome c from mitochondria, respiratory
inhibition and activation of caspases.search, Kaunas University of
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In vitro and in vivo studies have demonstrated cardioprotective
effects of estrogens in a number of pathologies. It has been shown that
17β-estradiol, the major endogenous estrogen, reduces the extent of
irreversible ischemic myocardial injury, infarct size, ischemia/reperfu-
sion-induced apoptotic cell death, ventricular arrhythmias, and such
effects have been detected in both male and female rat hearts [1–3].
Despite that, the molecular mechanism(s) of estradiol-induced cardi-
oprotection remains elusive. Estrogens are known to mediate their
biological effects through genomic and non-genomic pathways.
Classical pathwayof estrogen action ismediated bybinding of estrogens
to nuclear estrogen receptors which leads to altered expression of
certain genes involved in cardioprotective mechanisms [3–5]. In
addition, estrogens can exert rapid, transcription-independent effects
which may involve membrane-initiated activation of signaling path-
ways such as activation of phophatidylinositol-3-kinase (PI3K)-Akt
cascade [5–7]. Actions of Akt kinase in cells are diverse, cell type-
dependent, but the common feature is that Akt usually activates pro-survival, anti-apoptotic pathways. Akt is known to phosphorylate a
variety of down-streamkinases and othermolecules including glycogen
synthase kinase (GSK), endothelial nitric oxide synthase (eNOS), etc. In
line with that, using in vitro models of brain ischemia and oxidant-
induced skeletal muscle cell death, it was demonstrated that protective
effects of 17β-estradiol are mediated by activation of PI3K/Akt and
inactivationofGSK-3β [8,9]. Itwasalso shown that PI3K,Akt andprotein
kinase C-epsilon (PKC-ε) are involved in 17β-estradiol-induced
protection against ischemia/reperfusion-induced heart injury and
cardiomyocyte apoptosis [10,11]. However, there is limited knowledge
regarding the downstream molecular targets of the estrogen-activated
protein kinases that actually promote cell survival during heart
ischemia/reperfusion.
Mitochondrial damage, particularly opening of mitochondrial
permeability transition pore (MPTP), is thought to be critical in
ischemia/reperfusion-induced heart injury [12,13]. The molecular
structure of MPTP is still under debate but the consequences of
opening of this large, non-speciﬁc pore in the mitochondrial inner
membrane include mitochondrial depolarization, release of cyto-
chrome c from mitochondria, inhibition of oxidative phosphorylation
leading to cell death [14,15]. Pharmacological inhibitors of MPTP or
treatments of the hearts resulting in inhibition of MPTP (such as
ischemic or pharmacological preconditioning) have been shown to be
effective in reducing myocardial infarct size and improving heart
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prevent calcium-induced MPTP in isolated heart mitochondria [17].
Recently we have determined that short-term treatment of hearts
with estradiol protects against ischemia-induced MPTP, release of
cytochrome c from mitochondria, subsequent inhibition of mitochon-
drial respiration, caspase activation and nuclear apoptosis [18].
In this study, we aimed to investigate whether cardioprotective
effects of estradiol against ischemia-inducedMPTP andmitochondrial
dysfunction are mediated by activation of signaling kinases in the
perfused rat heart model. Using pharmacological inhibitors of protein
kinases we show that rapid protective effect of estrogens against
ischemic injury is mediated by signal transduction cascades (which
involve Akt, NO synthase, guanylyl cyclase, protein kinase G) that
converge on mitochondria making them more resistant to opening of
ischemia-induced permeability transition pore and subsequent
release of cytochrome c.
2. Materials and methods
The procedures used in this study are approved by the European
Convention for the protection of vertebrate animals used for experi-
mental and other purposes and according to the Republic of Lithuania
law on the care, keeping and use of animals (License of State Veterinary
Service for Working with Laboratory Animals No. 0006).
2.1. Heart perfusion
Hearts from 2 to 3 months old female Wistar rats were used in
experiments. The hearts were perfused on Langendorff perfusion
systemwith Krebs–Henseleit solution (11 mM glucose, 118 mMNaCl,
25 mM NaHCO3, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM CaCl2, 1.7 mM
MgSO4 and 0.7 mM Na pyruvate, pH 7.2 at 37 °C, saturated with
95% O2–5% CO2, at a pressure of 80 cm H2O) for 15min with 100nM
17β-estradiol. Control hearts were perfused for the same time but
without estradiol. In some experiments where inhibitors were used,
5 μM Akt kinase inhibitor IV (from Calbiochem), 100 μM L-NAME
(N (G)-nitro-L-arginine methyl ester), the NOS inhibitor (from
Sigma), 1 μM KT5823, the protein kinase G inhibitor (from Sigma),
25 μM ODQ (1H-[1,2,4]oxadiazolo [4,3-a]quinoxalin-1-one), the
guanylyl cyclase inhibitor (from Sigma), they were added to the
perfusion media 5–15 min prior to perfusion with estradiol. 1 μM
GSK-3ß kinase inhibitor I (from Calbiochem) was added to perfusion
medium without estradiol. After perfusion stop-ﬂow ischemia was
induced for 60 min. Coronary ﬂow ratewas 9 ml/min andwas similar
in all experimental groups.
2.2. Preparation of cytosolic and mitochondrial fractions
Hearts were cut into small pieces and homogenized in the isolation
buffer (10 ml/g of tissue) containing 180 mM KCl, 20 mM Tris–HCl,
1 mM EGTA, pH 7.3 at 2 °C temperature. Cytosolic and mitochondrial
fractions were separated by differential centrifugation (5 min×750g,
10 min×6800g). Post-mitochondrial supernatant was additionally
centrifuged for 30 min at 10,000g and the resulting supernatant was
used for determination of caspase activity. Total cytosolic and
mitochondrial protein was measured by a modiﬁed Biuret method
[19].
2.3. Measurement of mitochondrial respiration
Mitochondrial respiration rate was measured with a Clarke-type
oxygen electrode at 37 °C in 1 ml incubation buffer containing
110 mM KCl, 2.24 mMMgCl2, 10 mM Tris–HCl, 5 mM KH2PO4, 4 IU/ml
creatine kinase, 50 mM creatine, and respiration substrate 1 mM
pyruvate+1 mM malate or 5 mM succinate+1 μM rotenone (pH
7.2). Mitochondrial state 3 respiration rate was achieved by adding1 mM ATP that in the presence of creatine kinase and creatine is
converted into ADP.
2.4. Measurement of cytochrome c content
Total cytochrome c content was determined in mitochondria
solubilized with 1% Triton X-100 (w/v). Sodium hydrosulphite-
reduced minus hydrogen-peroxide-oxidized absorption spectra dif-
ference was recorded with a Hitachi-557 spectrophotometer. Cyto-
chrome c content was estimated by using the absorption difference at
thewavelengthpair 550/535 nmand ε=14.5 mM−1 cm−1asdescribed
in [20].
2.5. Measurement of mitochondrial calcium retention capacity
Mitochondrial capacity to accumulate calcium was measured
ﬂuorimetrically using Calcium Green-5N (Molecular Probes), excita-
tion at 506 nm, emission at 535 nm. The incubation medium
contained 200 mM sucrose, 10 mM Tris–HCl, 1 mM KH2PO4, 10 µM
EGTA, 0.3 mM pyruvate plus 0.3 mM malate, pH 7.4, 25 °C, ﬁnal
volume 200 µl. Calibration of the signal was achieved by the addition
of known amounts of CaCl2. Experiments were started by the addition
of 0.2 mg/ml mitochondria then 10 µM CaCl2 pulses were added until
opening of permeability transition pore occurred which was recorded
as large increase in ﬂuorescence. In some experiments 20 μM
atractyloside or 1 μM cyclosporin A (both from Sigma) was added to
the incubation buffer.
2.6. Measurement of caspase activity
Activity of caspases was measured as described in [21]. 1 mg/ml of
total cytosolic protein was incubated for 30 min in buffer containing
10% sucrose, 50 mM HEPES, 1 mM MgCl2, 1 mM ATP (pH 7.4, 37 °C)
and 0.1 mM z-DEVD-p-nitroanilide (Alexis), a caspase-3 substrate.
The hydrolysis of caspase substrate was followed spectrophotomet-
rically at 405 nm and was calibrated with p-nitroanilide. DEVD-
cleaving activity was completely suppressed by 0.02 mM DEVD-CHO
(Alexis), a reversible inhibitor of caspase-3.
2.7. Statistical analysis
Data are expressed as means±S.E. of at least 3 separate experi-
ments. Statistical comparison between experimental groups was
performed using ANOVA followed by Tukey or LSD tests. A value of
pb0.05 was considered statistically signiﬁcant.
3. Results
3.1. Effects on mitochondrial calcium retention capacity
First we investigated whether perfusion of the hearts with 17β-
estradiol can increase mitochondrial resistance to opening of MPTP. In
these experiments, hearts were perfused with 100 nM 17β-estradiol,
then subsequently isolated mitochondria were treated with pulses of
Ca2+ and extramitochondrial Ca2+ concentration was measured by
following changes in ﬂuorescence of dye Calcium Green. As can be
seen from Fig. 1A, added Ca2+ was rapidly taken up by mitochondria,
and after sufﬁcient loading mitochondria start to abruptly release
accumulated Ca2+ due to opening of MPTP. Therefore, amount of Ca2+
necessary to trigger this massive release of Ca2+ from mitochondria
(or calcium retention capacity, CRC) reﬂects the sensitivity of
mitochondria to Ca2+-induced opening of MPTP. In our experimental
settings, there was no signiﬁcant difference in the rate of calcium
uptake into mitochondria isolated from control and estradiol-treated
hearts (Fig. 1A). However, we found that CRC of mitochondria isolated
from estradiol-perfused hearts was statistically signiﬁcantly increased
Fig. 1. Estradiol increases mitochondrial Ca2+ retention capacity via activation of
protein kinase G. (A) Representitive curves of the measurement of Ca2+ retention
capacity of isolated rat heart mitochondria. Pulses of 10 μM CaCl2 were added to
isolated mitochondria until large increase in extramitochondrial Ca2+ was observed as
a result of MPTP opening. Typical experiment on mitochondria isolated from untreated
(Control) and estradiol-perfused (+Estradiol) hearts are presented. +CsA—control
mitochondria incubated in the presence of 1 μM cyclosporin A; RFU—relative
ﬂuorescence units. (B) Statistical data of the effects of estradiol-perfusion and other
factors on the mitochondrial Ca2+ retention capacity. Rat hearts were perfused with
Krebs–Henseleit solution only (control group) or with 100 nM 17β-estradiol (estradiol
group) or with 1 µM of PKG inhibitor KT5823 for 5 min prior to perfusion with estradiol
(KT+estradiol group) or with 1 μM GSK-3ß kinase inhibitor I (GSK inhibitor group). In
A and B: isolated mitochondria (0.2 mg/ml) were added to 200 μl incubation buffer
containing 200 mM sucrose, Tris–HCl 10 mM, KH2PO4 1 mM, EGTA 10 μM, 0.3 mM
pyruvate plus 0.3 mM malate, pH 7.4, where indicated, 1 μM cyclosporin A (+CsA) or
20 μM atractyloside (+Atr) were added to incubation buffer and mitochondrial Ca2+
accumulation was measured ﬂuorimetrically using Calcium Green-5 N as described in
Materials and methods. Ca2+ retention capacity of control mitochondria was 1508±
209 nmol/mg protein and was equated to 100 %. *—statistically signiﬁcant effect, if
compared to control; #—statistically signiﬁcant effect of KT5823, if compared to
estradiol group. Means±standard errors of 3–10 separate experiments are presented.
Fig. 2. Inhibitors of Akt, NOS, GC and PKG block protective effect of estradiol against
ischemia-induced release of cytochrome c from mitochondria. Hearts were perfused
with Krebs–Henseleit solution only (control group), then 60 min stop-ﬂow ischemia
was induced (60 min ischemia group) or hearts were perfused with 100 nM 17β-
estradiol prior to 60 min stop-ﬂow ischemia (estradiol+60 min ischemia group).
Where indicated, hearts were perfused with inhibitors: 1 μM KT5823, 100 μM L-NAME,
5 μM Akt inhibitor IV (Akt Inh) or 25 μM ODQ. Mitochondrial content of cytochrome c
was measured as described in Materials and methods. *—Statistically signiﬁcant effect
compared to control; #—statistically signiﬁcant effect compared to the estradiol +60min
ischemia group; ^—statistically signiﬁcant effect compared to 60 min ischemia group.
Means±standard errors of 3–10 separate experiments are presented.
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suggesting that perfusion of the hearts with estradiol can trigger a
mechanism which results in desensitization of MPTP to calcium. As
can be expected, in the presence of the MPTP inhibitor cyclosporin A
[22], the CRC of normal mitochondria increased by 58% compared to
untreated control (Fig. 1A, B). Addition of cyclosporin A to
mitochondria from estradiol-perfused hearts had no statistically
signiﬁcant effect on RCR (Fig. 1B) suggesting that perfusion of hearts
with estradiol can enhance mitochondrial capacity to accumulate
calcium to a similar extend as cyclosporin A. Another modulator of
MPTP—atractyloside (which is known to sensitize MPTP to calcium
[23]) when added directly into the mitochondrial incubation buffer
decreased CRC of normal mitochondria by 20% compared to control in
the absence of atractyloside (Fig. 1B). In contrast, mitochondria
isolated from estradiol-perfused hearts were resistant to atractylo-
side-mediated MPTP opening: in the presence of atractyloside their
CRC was signiﬁcantly higher than CRC of normal, not treated with
estradiol mitochondria (Fig. 1B). Importantly, when hearts were pre-perfused with estradiol in the presence of KT5823 (a selective
inhibitor of PKG) the CRC of subsequently isolated mitochondria
was markedly reduced and was similar to the untreated control level
(Fig. 1B). Similarly to estradiol, pre-perfusion of the hearts with
inhibitor of GSK 3β (a protein kinase which, when active, facilitates
MPTP opening [24,25]) resulted in increased by 23% capacity of
mitochondria to accumulate calcium before MPTP opening (Fig. 1B).
Altogether, the results indicate that treatment of the hearts with
estradiol desensitizes mitochondria to calcium-induced MPTP and
this may be mediated by activation of protein kinase G (PKG).3.2. Effects on ischemia-induced loss of cytochrome c from mitochondria
and respiration
Next we investigated whether similar mechanism–estrogen-
mediated desensitization of mitochondria to MPTP opening–can
protect heart mitochondria against ischemic injury. In these experi-
ments, loss of cytochrome c from mitochondria during ischemia was
considered as an indicator for MPTP opening based on our previous
ﬁndings that ischemia induces cyclosporin A-sensitive, thus MPTP-
related release of cytochrome c from mitochondria [21]. As can be
seen from Fig. 2, the content of cytochrome c in mitochondria isolated
from the hearts after 60 min ischemia decreased by 25% compared to
the control level. However, in mitochondria isolated from ischemic
hearts pre-perfused with estradiol the content of cytochrome c was
not signiﬁcantly different from control mitochondria. The protective
effect of estradiol was practically eliminated when hearts were pre-
perfused with either KT5823 (an inhibitor of PKG), or L-NAME (NO
synthase inhibitor): content of cytochrome c in mitochondria from
ischemic hearts treated with estradiol+KT5823 or estradiol+L-NAME
was similar as in ischemicmitochondria and substantially lower than in
estradiol-treated ischemic mitochondria (Fig. 2). Pre-perfusion of the
hearts with Akt inhibitor also partially abolished protective effect of
estradiol: the levels of cytochrome c in mitochondria isolated from
ischemic hearts treated with Akt inhibitor plus estradiol were lower by
12% compared to ischemia+estradiol group but still slightly higher
than in ischemic mitochondria.
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PKG in the signal transduction pathway. To investigate the involve-
ment of this enzyme in the protective effect of estradiol the hearts
were perfused with a selective inhibitor of guanylyl cyclase—ODQ. As
can be seen in Fig. 2, cytochrome c content in mitochondria isolated
from the ischemic hearts treated with ODQ plus estradiol was not
different from ischemic group and was substantially lower that in
ischemic mitochondria treated with estradiol-only. This suggests that
guanylyl cyclase is involved in estradiol-induced attenuation of
cytochrome c release from mitochondria during ischemia.
Perfusion of the normal, non-ischemic hearts with KT5823, ODQ,
L-NAME or Akt inhibitor had no effect on mitochondrial cytochrome c
level (Fig. 2). Similarly, pre-perfusion of the hearts with these
inhibitors had no effect on ischemia-induced loss of cytochrome c
from mitochondria (Fig. 2).
Administration of estradiol signiﬁcantly reversed the ischemia-
induced inhibition of mitochondrial State 3 respiration which was
previously shown to be related to the loss of cytochrome c from
mitochondria [26]. The protective effect of estradiol on respiration of
ischemic mitochondria was partially abolished when the hearts were
pre-perfused with KT5823 or L-NAME but the rates of state 3
respiration of mitochondria in these groups (ischemia+estradiol+
KT5823 and ischemia+estradiol+L-NAME)were still lower by about
40% than in control mitochondria (Fig. 3). Akt inhibitor almost fully
blocked the protective effect of estradiol: the respiratory rate of
mitochondria isolated from ischemic hearts treated with Akt inhibitor
plus estradiol was similar to ischemic mitochondria and substantially
lower than respiratory rate of estradiol-treated ischemic mitochon-
dria (Fig. 3). However, respiration of mitochondria isolated from
ischemic hearts pre-treated with estradiol+ODQ was not signiﬁ-
cantly different from ischemic mitochondria treated with estradiol-
only. Perfusion of the normal, non-ischemic hearts with KT5823, ODQ,
L-NAME or Akt inhibitor had no effect on mitochondrial respiratory
function (Fig. 3). Similarly, perfusion of hearts with these inhibitors
did not affect respiration of ischemia-damaged mitochondria (Fig. 3).
3.3. Effects on ischemia-induced caspase activation
We have previously shown that estradiol can protect heart
mitochondria from the ischemia-induced release of cytochrome c
and subsequent activation of caspases [18]. Here we tested whetherFig. 3. Inhibitors of Akt, NOS, GC and PKG block protective effect of estradiol against
ischemia-induced inhibition of mitochondrial respiration. Experimental conditions were
the same as in Fig. 2.Mitochondrial state 3 respiratory ratewith 1 mMpyruvate plus 1 mM
malate as substrates was measured as described inMaterials and methods. *—Statistically
signiﬁcant effect compared to control; #—statistically signiﬁcant effect compared to the
estradiol+60min ischemia group; ^—statistically signiﬁcant effect compared to 60 min
ischemia group. Means±standard errors of 3–10 separate experiments are presented.pre-perfusion of hearts with PKG inhibitor KT5823 would have any
effect on activity of caspases in estradiol-treated ischemic hearts.
Fig. 4 shows that caspase-3-like, DEVD-cleaving activity was signif-
icantly increased after 60 min of ischemia compared to control and
the activity was markedly inhibited with estradiol. Pre-perfusion of
the hearts with KT5823 reversed the protective effect of estradiol: the
activity of caspases in cytosols from ischemia+KT5823+estradiol-
treated hearts was ∼5-fold higher than in ischemia+estradiol-
treated hearts and was not signiﬁcantly different than in ischemic
hearts. Pre-perfusion with KT5823 alone had no statistically signiﬁ-
cant effect on activation of caspases in control or ischemic hearts
(Fig. 4). The data suggest that the effect of estradiol against ischemia-
induced caspase activation in the heart is mediated by PKG.
4. Discussion
In the present study we demonstrated that treatment of normal,
non-ischemic hearts with estradiol increases the resistance of
subsequently isolated mitochondria to calcium-induced MPTP open-
ing measured as calcium retention capacity. A known inhibitor of
MPTP—cyclosporin A, when added to isolated mitochondria, in-
creased CRC of normal mitochondria but was unable to alter CRC of
mitochondria isolated from estradiol-perfused hearts. This indicates
that treatment of the hearts with estradiol can enhance the resistance
of mitochondria to calcium-induced MPTP to a similar extend as
cyclosporin A. In agreement with previously published data [24,25],
we found that inhibition of GSK-3β activity during heart perfusion
desensitized mitochondria to MPTP opening. The effect of estradiol on
mitochondrial CRC was abolished by inhibitor KT5823 indicating that
it was mediated by PKG. In line with that, we showed that pre-
perfusion of the hearts with estradiol can protect mitochondria from
the ischemia-induced MPTP-mediated loss of cytochrome c, subse-
quent inhibition of mitochondrial respiration and caspase activation
acting at least partially via Akt, NOS, gyanylyl cyclase. And most
importantly, the study demonstrated that PKG inhibitor KT5823
abolished the protective effect of estradiol implying that PKG is
involved in the estrogen-triggered cascade leading to desensitization
of mitochondria to ischemia-induced MPTP and cytochrome c release.
To our knowledge, this is the ﬁrst report providing experimental
evidence of involvement of PKG in estrogen-mediated protection of
heart mitochondria against ischemia-induced MPTP-mediated injury.Fig. 4. Protein kinase G inhibitor KT5823 reverses the protective effect of estradiol against
ischemia-induced activation of caspases. Experimental conditions were the same as in
Fig. 2. Activity of caspases was measured spectrophotometrically at 405 nm in cytosolic
extracts using 0.1 mM z-DEVD-p-nitroanilide, a caspase-3 substrate. *—Statistically
signiﬁcant effect compared to control; #—statistically signiﬁcant effect of KT5823, if
compared to the 60 min ischemia+estradiol group. ^—statistically signiﬁcant effect of
estradiol, if compared to 60 min ischemia group. Means±standard errors of 3–5 separate
experiments are presented.
Fig. 5. Proposed mechanism by which estradiol protects heart mitochondria against
ischemic injury and cell death. Ischemia causesMPTP opening resulting in the release of
cytochrome c from mitochondria which causes activation of caspase-3 and leads to
apoptosis. MPTP opening as well as cytochrome c release is partially responsible for
mitochondrial respiratory inhibition, which may contribute to necrosis due to
mitochondrial deenergisation. Estradiol may activate the signaling cascade which
involves Akt, NOS, GC and PKG and results in blockage of MPTP-induced release of
cytochrome c from mitochondria preventing caspase-3 activation and respiratory
inhibition. As was described above in the paper, these effects can be abolished by Akt
kinase inhibitor IV, nitric oxide synthase inhibitor L-NAME, guanylyl cyclase inhibitor
ODQ and protein kinase G inhibitor KT5823. MPTP—mitochondrial permeability
transition pore, Akt—Akt kinase, NOS—nitric oxide synthase, GC—guanylyl cyclase,
PKG—protein kinase G.
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MPTP opening to a similar extend as cyclosporin A may imply that
estradiol-triggered signaling cascade affects cyclophilin D—a compo-
nent of MPTP and molecular target of cyclosporin A. Recently it has
been found that cyclophilin D can be phosphorylated by GSK-3β and
that in this phosphorylated form it favors MPTP opening [27]. Another
study demonstrated cGMP/PKG-mediated phosphorylation and inac-
tivation of GSK-3β [28]. Inhibition of GSK-3β by phosphorylation was
reported to desensitize MPTP [27], though mitochondrial location of
GSK-3βmay be controversial. Therefore, it is possible to speculate that
estradiol may trigger a signalling cascade which involves PKG and
results in phosphorylation-dependent inhibition of GSK-3β leading to
changes in the level of phosphorylation of cyclophilin D and
desensitization of MPTP to Ca2+. However, the precise molecular
mechanism how the signal from cytosolic PKG may be transmitted to
the possible intramitochondrial component(s) of MPTP remains to be
elucidated.
The present study identiﬁed Akt as a likely target of estradiol in the
cascade of events leading to prevention of ischemia-induced loss of
cytochrome c from mitochondria. It has been previously proposed
that the estradiol-activated estrogen receptor-PI3K-Akt pathway is
involved in the protection of cardiomyocytes against ischemia/
reperfusion-induced apoptosis [11] and heart dysfunction [29,30]. It
was demonstrated that inhibition of apoptosis was mediated by Akt
and further by hexokinase–mitochondria interaction which resulted
in stabilization of mitochondrial membranes [31]. Conﬁrming and
extending these ﬁndings we showed that the inhibitor of Akt
diminished protective effect of estradiol against ischemia-induced
release of cytochrome c from mitochondria and inhibition of
mitochondrial respiration suggesting that Akt may be an important
intermediate in the estrogen-triggered signaling cascade leading to
the increased resistance of mitochondria to ischemia-induced
opening of MPTP.
We have identiﬁed that the estradiol-triggered signalling cascade
also involves NOS, guanylyl cyclase and PKG as we showed that the
protective effect of estrogens disappears when the hearts are
preloaded with L-NAME, ODQ and KT5823. Akt is known to stimulate
NO production by NOS [32], and NOS has been shown to be important
in preconditioning, a phenomenon that renders the heart resistant to
ischemic injury [33]. Similarly, recent evidence has indicated that
PKG, which is activated by cyclic GMP in response to NO, is an
essential part of the signaling cascades in heart preconditioning and
postconditioning [34,35]. It has been shown that activated PKG can
block permeability transition pore in isolated brain [36], heart [37,38]
and liver mitochondria [39], although the mechanism of the blockage
remains unclear.
It is well-established that NO can control vascular tone (and
coronary ﬂow) in the heart. In principle, it is possible that protective
effect of estrogens may be mediated through activation of eNOS in
vasculature leading to improved blood supply to the heart during
ischemia/reperfusion. However, we think that this mechanism was
not signiﬁcant in our model of Langendorff-perfused heart where the
hearts were already maximally vasodilated due to partial hypoxia in
the absence of blood. Moreover, we showed that perfusion of the
normal, non-ischemic hearts with estradiol resulted in persistent,
long-lasting effect on subsequently isolated mitochondria rendering
them resistant to calcium-induced opening of MPTP. Therefore it is
likely that similar mechanism (estrogen-induced mitochondrial
resistance to opening of MPTP) was protecting the hearts during
ischemia. Augmented concentration of intracellular calcium has been
implicated as a causative damaging factor during ischemia/reperfu-
sion [40,41], inducing opening of MPTP. MPTP can cause loss of
mitochondrial cytochrome c due to swelling of the mitochondria and
rupture of the outer membrane. Thus, on the basis of this and previous
studies, we can conclude that the protective effect of estradiol may be
related to the inhibition of MPTP. On the other hand, we cannot ruleout the possibility that the protective effect of estradiol on
mitochondria in the perfused heart may be indirect as it has been
shown that estrogen-induced activation of eNOS may reduce the rise
of intracellular calcium [42]. However, this mechanism has been
shown to be mediated by NO-induced S-nitrosation of L-type calcium
channels. Therefore, it is unclear whether PKG has any role in such
mechanism.
In summary, the present study provides the evidence that estradiol
may protect the heart against ischemia-induced injury activating the
signaling cascade which involves Akt, NOS and PKG and results in
blockage of MPTP-induced release of cytochrome c from mitochon-
dria, respiratory inhibition and caspase activation (Fig. 5).Acknowledgments
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